Skip to content
DigeZyme®
  • DigeZyme®
    • Introduction
    • Digestive Enzymes
    • Significance of Enzymes
    • Salient Features
  • Insights
    • Rationale
    • Importance of Origin
    • Advantages
    • Enzyme Activity
  • Benefits
    • Clinical
    • Safety
    • Stability
  • IP Rights
    • Patents
  • About Sabinsa
    • Newsroom
      • Press Releases
      • Articles
      • Media Coverage
      • Ads
      • FAQs
  • Contact Us

Pavithra YN

ForsLean® addresses overall metabolic health and not just weight management, says Mr. Shaheen Majeed, President-Worldwide, Sabinsa

April 12, 2021May 2, 2019 by Pavithra YN

At April’s SupplySide East trade show, Sabinsa Corporation explained how its branded Coleus forskohlii extract ingredient, ForsLean…

Categories Press Release

Sabinsa Awarded New Patents For ForsLean®: New Scientific Discoveries Warrant Energy Balance Claims

April 12, 2021April 4, 2019 by Pavithra YN

Sabinsa announces that it has been awarded Japanese Patent Number 6472453, US Patent Number 10085963, and Australian Patent Number 2015351423

Categories Press Release

Sabinsa Publishes ForsLean® Safety Data in International Journal of Pharmacy & Pharmaceutical Research

April 12, 2021January 19, 2016 by Pavithra YN

Sabinsa Corporation and Sami Labs founder Dr. Muhammed Majeed was lead author of a paper published on the cumulative safety data of ForsLean®

Categories Press Release

Sabinsa Introduces Softgel Ready ForsLean® Soft Extracts Amid Exponential Growth in Coleus Demand: Company Cautions Against Low Quality Spam Knockoffs

April 12, 2021July 8, 2014 by Pavithra YN

Just in time for legitimate dietary supplement manufacturers to differentiate their products from the inferior spamtouted forskolin products driven…

Categories Press Release

Sabinsa Receives Payment from Creative Compounds for ForsLean® Trademark Infringement

April 12, 2021July 10, 2012 by Pavithra YN

An intellectual property battle lasting three years and reaching the US Supreme Court has ended at last with payment to Sabinsa Corporation by Creative Compound…

Categories Press Release

Creative Compounds’ Attempt to Continue Trademark Infringement of Sabinsa’s ForsLean® Rejected by US Supreme Court

April 12, 2021February 9, 2011 by Pavithra YN

Sabinsa’s International Presence Sabinsa Corporation’s protracted battle against Creative Compounds’ trade mark infringement of Sabinsa

Categories Press Release

Sabinsa Granted Forskolin Solubility Patent in China

April 12, 2021December 15, 2010 by Pavithra YN

Sabinsa’s International Presence The State Intellectual Property Office of the People’s Republic of China has granted Sabinsa a patent entitled…

Categories Press Release

Sabinsa’s ForsLean® Gets PI Numbers From TGA To Enter Australian Market

April 12, 2021July 12, 2010 by Pavithra YN

Sabinsa Corporation has received Product Information (PI) numbers for ForsLean® 10% and 20% from Australia’s TGA (Therapeutic Goods Administration)

Categories Press Release

US Appeals Court Finds Creative Compounds Guilty of Trademark Infringement Against Sabinsa’s ForsLean®

April 12, 2021June 14, 2010 by Pavithra YN

Sabinsa’s International Presence Sabinsa Corporation has achieved a significant victory in protecting its intellectual property investment in ForsLean®…

Categories Press Release

Sabinsa Secures International Forskolin Patent: Granted in Republic of South Africa & Singapore

April 12, 2021September 12, 2008 by Pavithra YN

Sabinsa has been granted a patent in South Africa and Singapore as part of its PCT application on “Process of preparing water soluble diterpenes and their app…

Categories Press Release
Older posts
Page1 Page2 Page3 Next →

Search

About Sabinsa

Sabinsa is a manufacturer, supplier and marketer of herbal extracts, cosmeceuticals, minerals, dietary supplements and specialty fine chemicals for the nutritional, cosmetic, pharmaceutical and food industries.

Read More..

Certificates

Kosher IFANCA Halal Certified
Non-GMO

Headquarters

Sabinsa Corporation

20 Lake Drive 

East Windsor

NJ 08520, USA

 

Tel : +1 732 777 1111

Fax: +1 732 777 1443

info@sabinsa.com

Global Contact List

USA India
Utah, USA Japan
Australia Poland
Brasil Korea
Canada South Africa
China Vietnam
Germany  

Contact us

    © 2025 Sabinsa. All Rights Reserved | Powered by Edkal Technologies | Privacy Policy | Sitemap | Terms of Use | Disclaimer

    ×

    Disclaimer

    US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

    EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.